Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zepbound
Biotech
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
The highest dose of Lilly's amylin-Zepbound combo yielded average weight loss of 54.1-pounds at 48 weeks, with A1C-lowering benefits shown, too.
Marissa Russo
Sep 30, 2026 1:52pm
Fierce Pharma
No more Nordisk as Novo goes it alone amid rebranding push
Sep 14, 2026 6:54am
Fierce Pharma
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
Endoscopic procedure can help slow weight rebound from GLP-1s
Apr 27, 2026 8:48am
BrightGene's oral drug sees up to 8% weight loss in early data
Mar 25, 2026 4:04am
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Feb 10, 2026 9:25am
